Glenmark Pharmaceuticals has announced that GRC 27864 is entering human trials. GRC 27864 targets Microsomal Prostaglandin E synthase-1 (mPGES-1) as a therapeutic target in pain management. Selective mPGES-1 inhibitors are expected to inhibit increased prostaglandin E2 (PGE2) production in the disease state without affecting other prostanoid metabolites and, consequently, may be devoid of the GI (gastrointestinal) and cardiovascular side effects seen with NSAIDs and COX-2 inhibitors, respectively.
Recent reports indicate that more than 1.5 billion people worldwide suffer from chronic pain in some form with a direct correlation between incidence rates and increasing age. It is estimated that, at some point in their lives, 20% of the global adult population suffers from pain with 10% of newly diagnosed cases of chronic pain being added each year.
Despite incremental advances in opioid-based or cyclooxygenase-based therapies, there has been little success in identifying and developing treatments based upon new targets that might overcome the limitations of currently available analgesic treatments for the management of chronic pain.
Glenmark has completed preclinical studies and Phase 1 enabling GLP studies for its selected lead molecule, GRC 27864 and has filed a Phase 1 application for first-in-human trial with the MHRA, UK. The Phase 1 studies are to be initiated soon and are likely to get completed by January 2015. Following this, Glenmark will also be initiating a proof of concept study in patients with acute pain.
PGE2 is a lipid mediator produced by arachidonic acid, which serves pivotal functions in disease conditions associated with fever, inflammation, and pain. mPGES-1 is a terminal enzyme in the PGE2 biosynthetic pathway and solely responsible for PGE2 synthesis during inflammation. Over expression of mPGES-1 is observed in various nonclinical animal models, such as RA, OA, atherosclerosis, experimental autoimmune encephalomyelitis, cancer, inflammatory bowel disease, multiple sclerosis, periodontitis, fibrosis, Parkinson's disease, and Alzheimer's disease.
On the contrary, mPGES-1 deleted cells produced significantly lower levels of PGE2 in response to inflammatory stimuli and were less sensitive to inflammatory and neuropathic pain, and refractory to the development of joint pathology in rodent arthritis models. Selective mPGES-1 inhibitors are expected to inhibit increased PGE2 production in the disease state without affecting other prostanoid metabolites and are, consequently, may be devoid of the GI and cardiovascular side effects seen with NSAIDs and COX-2 inhibitors, respectively, potentially making them suitable for chronic treatment of inflammatory diseases that are accompanied with pain.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- What's Hiding Under The Clouds Of Venus - Heavy Metal Frost?
- Dopamine Receptor Agonist Drugs Linked To Gambling And Hypersexuality
- Ashes And Vegetables: The Diet Of Roman Gladiators Was Rather Poor
- Moderate Pot Use By Adolescents Doesn't Hurt IQ
- Manly Men And Feminine Women Are Not Evolutionary Mandates - They Are Urban Ones
- New Pill-only Regimens Cure Patients With Hardest-to-treat Hepatitis C Infection
- Flow Machine: Hacking The Human Brain For Healing And Wellbeing
- "Since there's no actual link between vaccines and autism, I think the phrase Vaccines have been..."
- "I'll not argue that humanity made God in their image, because we sought to explain something we..."
- "I think we all are atheist, agnostics, and believers throughout our life time. I also, think some..."
- "The scenario mentioned above (Poor person shows up at emergency room with a fever... No health..."
- "Actually, I used to believe. It was what I was taught as a child and I was raised a Christian...."
- Mutagenesis: One way Europeans wish it was 1936 again
- Closer examination of risk factors for Latinos underscores cultural diversity
- Saving bees requires less pesticides, changing farming
- Could GM plants replace airport security scanners?
- In a battle of brains, chimpanzees match human toddlers
- ‘Urban farmers’ behind GMO labeling initiatives
- Alternate approach to traditional CPR saves lives
- Once CD8 T cells take on one virus, they'll fight others too
- 11 million will lose health insurance if ACA subsidies are eliminated, study finds
- Two Michigan high school students develop screening tools to detect lung and heart disease
- Even depressed people believe that life gets better